Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q3 2015 Net Income-$68.33K-$68.33KN/M vs Q3 2015 EPS Diluted-$0.03-$0.03N/M vs Q3 2015 Gross Profitderived$0−100.0%
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Operating Cash Flowderived$16,736N/M ended Sep 30, 2016 · filed Sep 8, 2017 · 343 d after period end